1. Home
  2. POWL vs TGTX Comparison

POWL vs TGTX Comparison

Compare POWL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Industries Inc.

POWL

Powell Industries Inc.

N/A

Current Price

$208.74

Market Cap

8.5B

Sector

Energy

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$50.13

Market Cap

7.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
POWL
TGTX
Founded
1947
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
7.6B
IPO Year
1995
2008

Fundamental Metrics

Financial Performance
Metric
POWL
TGTX
Price
$208.74
$50.13
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
$184.25
$49.80
AVG Volume (30 Days)
819.2K
2.3M
Earning Date
05-04-2026
05-04-2026
Dividend Yield
0.14%
N/A
EPS Growth
N/A
1746.67
EPS
3.81
0.17
Revenue
$448,716,000.00
$2,785,000.00
Revenue This Year
$11.20
$49.08
Revenue Next Year
$9.12
$26.69
P/E Ratio
$54.48
$290.41
Revenue Growth
13.34
N/A
52 Week Low
$178.05
$26.76
52 Week High
$612.50
$59.30

Technical Indicators

Market Signals
Indicator
POWL
TGTX
Relative Strength Index (RSI) 41.21 44.60
Support Level $181.33 $28.57
Resistance Level $248.33 $58.08
Average True Range (ATR) 14.39 2.39
MACD 1.39 -0.64
Stochastic Oscillator 38.17 37.80

Price Performance

Historical Comparison
POWL
TGTX

About POWL Powell Industries Inc.

Powell Industries Inc is a United States-based company that develops, designs, manufactures, and services custom-engineered equipment and systems for electrical energy distribution, control, and monitoring. The company's principal products comprise integrated power control room substations, custom-engineered modules, electrical houses, traditional and arc-resistant distribution switchgear and control gear, and so on. These products are applied in oil and gas refining, offshore oil and gas production, petrochemical, pipeline, terminal, mining and metals, light-rail traction power, electric utility, pulp and paper, and other heavy industrial markets. The company generates the majority of its sales from the United States, and the rest from Canada, Europe, Asia Pacific, and other regions.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: